This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

SORIN Acquires UCL Spin-off NeuroTECH

LOUVAIN-LA-NEUVE, Belgium, November 12, 2012 /PRNewswire/ --

SORIN, a global medical device company and a leader in the treatment of cardiovascular , has acquired  NeuroTECH ,  a spin-off of  Université catholique de Louvain    (UCL).

Established in the end of nineties, NeuroTECH was co-founded by M. Troosters and three members of UCL (Prof. C. Trullemans, Prof Cl. Veraart and Dr. J. Delbeke). During the first years of the company, the spin-off of two laboratories (Neural Rehabilitation Engineering and Microelectronics Laboratory) assisted in the development of a visual prosthesis in the frame of European grants. A world premiere took place in 1998, with the implantation of an optic nerve visual prosthesis at the Cliniques universitaires St-Luc, Brussels.

In 2002, the company identified a new application for the treatment of refractory epilepsy. A novel implantable vagus nerve stimulation system was developed. ADNS-300, CE marked, is able not only to stimulate but also to record compound action potentials from the vagus nerve, using this information to potentially personalize the therapy and provide an improved outcome. Chronic recording of the compound action potentials of the vagus nerve has been another world premiere for Neurotech, which it achieved in collaboration with the University of Gent's department of Epileptology of Prof. P. Boon. Other prototypes were also developed by NeuroTECH to evaluate the use of neurostimulation to treat either refractory obstructive sleep apnea, or movement disorders respectively.

Since its inception, SOPARTEC, a wholly owned subsidiary of UCL and manager of VIVES Louvain Technology Funds was one of the co-founders and an early investor in the company. From 2005 onwards, the company was funded by VIVES I and SRIW.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs